Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 12Thoracic 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Diarrhea 1Colitis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 38Docetaxel 23Paclitaxel 20Trastuzumab 19Cyclophosphamide 18Gemcitabine 17Carboplatin 17Magnetic Resonance Spectroscopy 16Radiotherapy 14Nivolumab 13Radiosurgery 12Surveys and Questionnaires 11Specimen Handling 10Fulvestrant 10fludarabine 9aldesleukin 9Vinorelbine 9Blood Specimen Collection 9Taxes 8Injections 8Drug Therapy 8Cisplatin 8Capecitabine 8Bevacizumab 8Standard of Care 7Psychiatric Rehabilitation 7Fluorodeoxyglucose F18 7Early Intervention, Educational 7sargramostim 6palbociclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Loperamide × Thoracic × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡